# Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

> **NCT05577728** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 2316 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** New use of semaglutide injection
- **DRUG:** New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)

## Key facts

- **NCT ID:** NCT05577728
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 2316 (ACTUAL)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577728, "Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05577728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*